NCCN Oncology Research Program (ORP)
TAGRISSO™ (osimertinib) Research Grant Opportunity – Submit by January 12, 2017
Study Proposal Submission-NCCN RMS
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP Investigator Steering Committee
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources (Members Only
NCCN Insights: Analytics, Research & Consulting
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees
NCCN Research & Business Resources
Find a clinical trial >
Since 1996, the adult oncology collaboration of Dana-Farber Cancer Institute, Brigham and Women's Hospital and Massachusetts General Hospital Cancer Center has enabled some of the world's leading specialists to coordinate research, training, and patient care. These Harvard Medical School-affiliated hospitals are members of Dana-Farber/Harvard Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center.
Patient care is provided at Dana-Farber/Brigham and Women’s Cancer Center and Massachusetts General Hospital Cancer Center. At each site patients are offered the highest standard of care and innovative treatments.
- Adult cancer care is organized into more than 12 multidisciplinary treatment programs including breast cancer, endocrine cancer, gastrointestinal cancer, genitourinary cancer, gynecological cancer, head and neck cancer, hematology, hematologic malignancies (leukemia, lymphoma & multiple myeloma) , melanoma, neuro-oncology, sarcoma, and thoracic oncology. Through each treatment program, patients have access to specialized cancer physicians, surgeons, radiation oncologists, nurses, social workers, and other staff. These clinicians work with patients and referring physicians to develop care plans. All aspects of diagnosis and treatment are available, from genetic and molecular testing to a full array of support services, including individual and group counseling.
- Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Massachusetts General Hospital Cancer Center are leaders in cancer research and rank as the top three independent recipients of National Institutes of Health research funding in the United States. Their collaboration brings together each institution's diverse capabilities in research to help speed the transition of new discoveries into effective patient therapies. Together, Dana-Farber/Brigham and Women's Cancer Center and Massachusetts General Hospital Cancer Center activate more than 15 new cancer trials each month and now have more than 700 active clinical trials underway. Thousands of patients a year are enrolled in clinical research trials which offer them access to promising new therapies and, at the same time, provide valuable information that may lead to better treatments for all cancer patients.
- Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Massachusetts General Hospital Cancer Center are each members of Dana-Farber/Harvard Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center.
For more than 60 years, Dana-Farber Cancer Institute and Children's Hospital Boston have worked together to provide the best care available for children with cancer. Known as Dana-Farber/Children's Hospital Cancer Care, these neighboring institutions provide a spectrum of services, from diagnosis to long-term management of all types of childhood cancers. Dana-Farber/Children's Stem Cell Transplantation Program is one of the oldest and largest programs in the nation and its Pediatric Brain Tumor Program is the largest in the region. Both programs remain at the forefront of research and technology and are among the most accomplished in the world. Furthermore, the David B. Perini, Jr. Quality of Life Clinic has helped thousands of survivors of childhood cancers cope with the long-term effects of the disease.